Soleno Therapeutics, Inc. (NASDAQ:SLNO) Receives Consensus Recommendation of "Hold" from Brokerages

Key Points

• Consensus "Hold": Thirteen analysts cover Soleno with a consensus rating of "Hold" (1 sell, 8 hold, 4 buy) and an average 12‑month price target of $89.20.
• Recent downgrades and $53 catalyst: Several brokerages (HC Wainwright, Cantor Fitzgerald, Zacks, Wolfe Research, Lifesci Capital, etc.) recently cut ratings and targets—many to a $53 level—and the stock (~$52.51 open) has rallied on takeover chatter reportedly tied to a $53/share cash deal.
• Heightened legal/headline risk: Multiple law firms have filed or solicited plaintiffs in securities class actions related to Soleno’s Phase 3 disclosures, with a May 5, 2026 lead‑plaintiff deadline that could amplify short‑term downside pressure.

Soleno Therapeutics, Inc. (NASDAQ:SLNO - Get Free Report) has earned a consensus recommendation of "Hold" from the thirteen research firms that are currently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and four have issued a buy rating on the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $89.20.

A number of research analysts have recently weighed in on the company. HC Wainwright lowered Soleno Therapeutics from a "buy" rating to a "hold" rating and cut their price objective for the company from $100.00 to $53.00 in a research report on Wednesday. Cantor Fitzgerald lowered Soleno Therapeutics from an "overweight" rating to a "hold" rating and cut their price objective for the company from $123.00 to $53.00 in a research report on Monday. Zacks Research lowered Soleno Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, February 3rd. Lifesci Capital lowered Soleno Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Monday. Finally, Wolfe Research lowered Soleno Therapeutics from an "outperform" rating to a "hold" rating in a research report on Tuesday.

Soleno Therapeutics Price Performance

NASDAQ:SLNO opened at $52.51 on Friday. The company has a quick ratio of 5.55, a current ratio of 5.80 and a debt-to-equity ratio of 0.11. The business's 50-day simple moving average is $38.63 and its two-hundred day simple moving average is $47.86. The stock has a market cap of $2.71 billion, a PE ratio of 228.31 and a beta of -2.81. Soleno Therapeutics has a 52 week low of $29.43 and a 52 week high of $90.32.

Soleno Therapeutics (NASDAQ:SLNO - Get Free Report) last posted its quarterly earnings results on Wednesday, February 25th. The company reported $0.80 EPS for the quarter, beating analysts' consensus estimates of $0.64 by $0.16. The business had revenue of $91.73 million for the quarter, compared to the consensus estimate of $88.55 million. As a group, analysts forecast that Soleno Therapeutics will post -3.72 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of Soleno Therapeutics by 1.1% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 17,360 shares of the company's stock valued at $1,242,000 after purchasing an additional 189 shares in the last quarter. Raymond James Financial Inc. purchased a new position in shares of Soleno Therapeutics during the second quarter valued at about $25,000. Avanza Fonder AB grew its position in shares of Soleno Therapeutics by 11.2% during the fourth quarter. Avanza Fonder AB now owns 3,195 shares of the company's stock valued at $148,000 after purchasing an additional 323 shares in the last quarter. Principal Financial Group Inc. grew its position in Soleno Therapeutics by 11.9% in the third quarter. Principal Financial Group Inc. now owns 3,197 shares of the company's stock worth $216,000 after acquiring an additional 340 shares in the last quarter. Finally, New York State Common Retirement Fund grew its position in Soleno Therapeutics by 2.4% in the third quarter. New York State Common Retirement Fund now owns 15,600 shares of the company's stock worth $1,055,000 after acquiring an additional 360 shares in the last quarter. Hedge funds and other institutional investors own 97.42% of the company's stock.

More Soleno Therapeutics News

Here are the key news stories impacting Soleno Therapeutics this week:

• Positive Sentiment: Zacks and other outlets note a recent sharp rally tied to acquisition activity/sector M&A — reports point to a cash deal at $53/share as the catalyst that pushed SLNO higher in recent sessions, supporting a takeover premium argument. Soleno Therapeutics Stock Rallies 56.4% in a Week: Here's Why
• Neutral Sentiment: Analysts’ sector commentary (Gilead/others including SLNO) provides context on competitive dynamics and product transfers in endocrinology/rare disease, useful for investors assessing strategic value. Analysts Offer Insights on Healthcare Companies
• Negative Sentiment: Multiple law firms have filed or solicited plaintiffs in a securities class action tied to alleged misstatements about SLNO’s Phase 3 program; a May 5, 2026 lead‑plaintiff deadline is driving outreach and increases perceived legal risk. Rosen Law Firm Encourages Soleno Investors to Secure Counsel
• Negative Sentiment: Additional firms (Faruqi & Faruqi, Bragar Eagel & Squire, Hagens Berman, Pomerantz, Bronstein Gewirtz & Grossman, Robbins Geller, Bernstein Liebhard, Glancy Prongay, Kahn Swick & Foti and others) are issuing notices and filings — the volume of solicitations amplifies headline risk and may pressure the stock while outcomes remain uncertain. Bragar Eagel & Squire Announces Class Action
• Negative Sentiment: Several brokerages (HC Wainwright, Piper Sandler, Robert W. Baird, Wolfe Research, TD Cowen, Cantor Fitzgerald, Lifesci Capital and others) downgraded SLNO or cut ratings/targets this week, reducing sell‑side support and contributing to downward momentum. Soleno Therapeutics Cut to "Hold" at Lifesci Capital

About Soleno Therapeutics

Soleno Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of therapies for rare and orphan diseases. Headquartered in Redwood City, California, Soleno leverages a precision medicine approach to identify and advance small‐molecule treatments that address underlying genetic and metabolic dysfunctions. The company's scientific strategy centers on repurposing and reformulating existing compounds to maximize therapeutic benefit in underserved patient populations.

The company's lead candidate, diazoxide choline controlled release (DCCR), is being investigated for the treatment of Prader-Willi syndrome (PWS), a complex neurodevelopmental disorder characterized by insatiable appetite, hormonal imbalances and behavioral challenges.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.